WO2007000924A1 - Préparation pharmaceutique comprenant une substance susceptible d'inhiber ou de promouvoir l'activité de la progranuline et méthode de criblage pour la recherche d'une substance susceptible d'inhiber ou de promouvoir l'activité de la progranuline - Google Patents

Préparation pharmaceutique comprenant une substance susceptible d'inhiber ou de promouvoir l'activité de la progranuline et méthode de criblage pour la recherche d'une substance susceptible d'inhiber ou de promouvoir l'activité de la progranuline Download PDF

Info

Publication number
WO2007000924A1
WO2007000924A1 PCT/JP2006/312428 JP2006312428W WO2007000924A1 WO 2007000924 A1 WO2007000924 A1 WO 2007000924A1 JP 2006312428 W JP2006312428 W JP 2006312428W WO 2007000924 A1 WO2007000924 A1 WO 2007000924A1
Authority
WO
WIPO (PCT)
Prior art keywords
activity
prodara
disease
substance
urine
Prior art date
Application number
PCT/JP2006/312428
Other languages
English (en)
Japanese (ja)
Inventor
Akifumi Matsuyama
Shizuya Yamashita
Yoshiki Sawa
Yuzuru Kanakura
Original Assignee
Osaka University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University filed Critical Osaka University
Publication of WO2007000924A1 publication Critical patent/WO2007000924A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • composition containing a substance that suppresses or promotes progranulin activity, and screening method for a substance that suppresses or promotes progranulin activity
  • the present invention relates to prodara-yulin activity for treating or preventing a disease caused by an increase or decrease in fat thread and tissue cells and a disease caused by an increase or decrease in Z or macrophage activity.
  • a pharmaceutical composition comprising a substance that suppresses or promotes and a substance for treating or preventing a disease caused by an increase or decrease in adipose tissue 'cells and a disease caused by an increase or decrease in Z or macrophage activity.
  • the present invention relates to a disease whose pathogenesis is an increase or decrease in Z or macrophage activity, or a method for examining the predisposition thereof.
  • Macrophages are cells that produce various substances and also infiltrate adipose tissue. Macrophage strength Among the substances produced, it is known that inflammatory site force-in is deeply involved in inflammatory diseases. Suppress the action of specific site force in to treat such diseases Drug development has been carried out. However, since such diseases are caused by many substances involved in various forms, it is considered that drugs that suppress the excessive action of the entire cyto-force-in producing cell are effective.
  • Non-patent document 1 Hopkins PN et al., Curr Opin Lipidol. 1996 Aug; 7 (4): 241-53
  • Non-patent document 2 Moller DE et al., Annu Rev Med. 2005; 56: 45-62
  • the problem to be solved by the present invention is to clarify the relationship between the decrease in HDL level and the accumulation of visceral fat and metabolic syndrome, and a substance useful for the treatment and prevention of metabolic syndrome and various diseases that accompany this, As well as the mechanism of macrophage activation, to find substances useful for the treatment and prevention of various diseases such as inflammatory diseases and arteriosclerosis, and to find screening methods for them. .
  • HDL suppresses visceral fat accumulation, thereby suppressing metabolic syndrome and suppressing macrophage activity.
  • macrophages produce prodranulin, and produralurin acts on macrophages to make them active and induce cytokines such as pro-inflammatory cytokines and physiologically active substances. It was found to secrete and induce differentiation of adipose precursor cells to adipocytes. Based on these findings, the present invention has been completed.
  • the present invention provides:
  • Adipose thread and tissue-Pharmaceutical composition containing a substance that suppresses produra-urine activity to treat or prevent diseases caused by increased cells and diseases caused by increased Z or macrophage activity object,
  • composition according to (1) wherein the substance that suppresses proskyulin activity is an anti-progranulin antibody
  • the disease is selected from the group consisting of obesity, diabetes, hypertension, hyperlipidemia, metabolic syndrome, arteriosclerotic disease, ischemic heart disease, inflammatory disease, arteriosclerosis, cirrhosis.
  • a pharmaceutical composition comprising the substance
  • composition according to (5) wherein the disease is selected from the group consisting of malnutrition, lupus, lipodystrophy, immune disease, and malignant tumor,
  • Treatment or prevention of a disease caused by an increase in adipose tissue 'cells and a disease caused by an increase in Z or macrophage activity characterized by administering a substance that suppresses prodara-urine activity Method
  • a substance that suppresses prodara-urine activity is HDL or apolipoprotein AI, or an anti-prodara-urin antibody, (7)
  • the disease is selected from the group consisting of obesity, diabetes, hypertension, hyperlipidemia, metabolic syndrome, arteriosclerotic disease, ischemic heart disease, inflammatory disease, arteriosclerosis, cirrhosis.
  • a disease caused by a decrease in adipose tissue 'cells characterized by administration of prodara-yulin and a substance that promotes Z or prodara-yulin activity, and caused by a decrease in Z or macrophage activity.
  • a method of treating or preventing a disease characterized by administration of prodara-yulin and a substance that promotes Z or prodara-yulin activity, and caused by a decrease in Z or macrophage activity.
  • the disease is selected from the group consisting of obesity, diabetes, hypertension, hyperlipidemia, metabolic syndrome, arteriosclerotic disease, ischemic heart disease, inflammatory disease, arteriosclerosis, cirrhosis.
  • a method for screening a substance that suppresses prodara-urine activity comprising the following steps:
  • the differentiation or the activity of the adipocytes, or the macrophage activity is suppressed as compared with the differentiation or activity when the adipose precursor cells or macrophages are similarly cultured in a medium not containing a candidate substance.
  • a method for screening a substance that promotes prodara-urine activity comprising the following steps:
  • the differentiation or the activity of the adipocytes, or the macrophage activity is the same as that obtained when the adipose precursor cells or the macrophages are similarly cultured in a candidate substance-free medium or A method that indicates that the candidate substance is a substance that promotes prodara-urine activity when promoted compared to activity,
  • step (a) The method according to (17) or (18), wherein in step (a), Prodara-Yulin is supplied by macrophages,
  • a pharmaceutical composition for treating or preventing a disease caused by an increase in adipose tissue / cell and a disease caused by an increase in Z or macrophage activity comprising the substance according to (20),
  • a pharmaceutical composition for treating or preventing adipose tissue, a disease caused by a decrease in cells and a disease caused by a decrease in Z or macrophage activity comprising the substance according to (22),
  • a prodrug-lily for treating or preventing a disease caused by an increase in fat thread and woven cells and a disease caused by an increase in Z or macrophage activity.
  • Prodara-Yulin and Z for the treatment or prevention of pharmaceutical compositions containing substances that suppress the activity of adenine, adipose tissue, diseases caused by cell loss, and diseases caused by reduced Z or macrophage activity
  • a pharmaceutical composition containing substances that promote prodara-urine activity a method for screening these substances and substances obtainable thereby, and assessing prodara-urine amount and Z or activity
  • a disease or a predisposition thereof caused by an increase or decrease in adipose tissue / cell, and a method for examining a disease or predisposition thereof caused by an increase or decrease in Z or macrophage activity are provided.
  • FIG. 1 shows the results of SDS-PAGE of purified macrophage-derived HDLZ apolipoprotein AI binding protein.
  • FIG. 2 is a graph showing the expression of prodara-yulin in macrophages by quantitative PCR.
  • FIG. 3 is an immunoplot showing the expression and secretion of prondulin in macrophages.
  • FIG. 4 is a graph showing the promotion of the differentiation of preadipocytes into adipocytes by co-culture with macrophages, and the suppression thereof by HDL and apolipoprotein AI.
  • FIG. 5 is a graph showing suppression of differentiation of preadipocytes into adipocytes by anti-progranulin antibody.
  • FIG. 6 is a graph showing the promotion of differentiation of preadipocytes into adipocytes by prondulin, and the suppression thereof by HDL and apolipoprotein AI.
  • FIG. 7 is a graph showing an increase in TNF- ⁇ expression in macrophages by proongulin using quantitative PCR and its suppression by HDL and apolipoprotein ⁇ -I.
  • FIG. 8 is a graph showing the increase in MMP-9 expression in macrophages by proongulin using quantitative PCR and its suppression by HDL and apolipoprotein AI.
  • FIG. 9 is a graph showing suppression of MMP-9 expression in macrophages by an anti-Prodara-Yulin antibody using quantitative PCR.
  • the present invention relates to a proline activity for treating or preventing a disease caused by an increase in adipose tissue / cell and a disease caused by an increase in Z or macrophage activity.
  • the present invention relates to a pharmaceutical composition containing an inhibitory substance.
  • Cells refer to adipose precursor cells, adipocytes, undifferentiated cells, stem cells, and the like, and Z or tissues containing these cells.
  • the increase in adipose tissue and cells includes an increase in the number of adipose tissue 'cells, an increase in the volume of single adipocytes, and an increase in the activity of adipose tissue' cells.
  • Adipose tissue Diseases caused by an increase in cysts can be caused directly or indirectly by an increase in adipose tissue cells, such as obesity, diabetes, hypertension, hyperlipidemia, Metabolic syndrome, arteriosclerotic disease, ischemic heart disease and the like can be mentioned.
  • Macrophage activity refers to phagocytosis of macrophages, function as antigen-presenting cells, and the action of producing or secreting Z or physiologically active substances such as MMP-9, TNF-a, IL 6, or cytokines This refers to any action that macrophages have, and its rise is, for example, an increase in the action of producing or secreting a physiologically active substance or cyto force-in.
  • Diseases caused by increased macrophage activity may be those caused directly or indirectly by increased macrophage activity, such as inflammatory diseases, arteriosclerosis, ischemic heart disease, cirrhosis, etc. Can do.
  • the term "prodara-urine activity” refers to the action of inducing or promoting the differentiation of produralurine into adipocytes of adipose precursor cells, and the action of increasing or maintaining the activity of adipocytes. And an action that increases or maintains macrophage activity.
  • the increase in “Prodara-Yulin activity” promotes the differentiation of preadipocytes into adipocytes to increase the number of adipocytes, or increase the activity of adipocytes, or MMP-9 from macrophages, Production and secretion of physiologically active substances such as TNF-a and IL-6 or cyto force-in may increase.
  • prodara-urine activity means that the above “prodara-urine activity” is incomplete or May be partly suppressed or completely extinguished. Specifically, reducing the promotion of differentiation rate from preadipocytes to adipocytes, blocking the induction of differentiation, and completely or incompletely stopping induced or promoted differentiation, and adipocytes This includes completely or incompletely blocking the action on macrophages, and further completely or incompletely blocking the action on macrophages. Therefore, suppression of prodara-urine activity reduces the number of adipocytes produced or reduces the activity of adipocytes, or bioactive substances such as MMP-9, TNF-a, IL6 Production and secretion of force-in may be reduced.
  • Substances that inhibit the activity of prodara-urine of the present invention include those capable of acting directly or indirectly on prodara-urine.
  • the substance that suppresses produra-urine activity may be capable of suppressing the action of produralurin described above, for example, by binding directly or indirectly to produralurin.
  • HDL and its main component apolipoprotein AI, anti-prodara-urine antibody, or a substance known as an antagonist / inhibitor of prodralurin, etc., preferably HDL Or apolipoprotein AI, or anti-prodara-urine antibody.
  • the anti-prodara-urin antibody may be a monoclonal antibody or a polyclonal antibody.
  • the pharmaceutical composition of the present invention generally contains a substance that suppresses prodara-urine activity, an excipient, an additive, and Z or a carrier. If desired, the pharmaceutical composition of the present invention may further contain one or more substances that inhibit prodara-urine activity.
  • the dosage form of the pharmaceutical composition of the present invention is appropriately selected depending on the condition of the target, target site, etc. For example, it may be an oral preparation such as a powder, a tablet, a capsule or a syrup, or a liquid such as a liquid for injection or infusion.
  • the amount of the substance that suppresses produra-urine activity in the pharmaceutical composition of the present invention depends on various conditions such as the age, sex, or history of the subject, and the type and severity of the disease to be treated or prevented. It is selected as appropriate.
  • the present invention relates to a disease whose pathogenesis is caused by a decrease in adipose tissue and cells.
  • a pharmaceutical composition comprising prodara-urine and a substance that promotes z- or prodara-urine activity for treating or preventing a disease caused by reduced z or macrophage activity.
  • the reduction of adipose tissue / cell includes a decrease in adipose tissue / cell number, a decrease in the volume of a single adipocyte, and a decrease in adipose tissue 'cell activity.
  • the disease caused by a decrease in adipose tissue or cells may be a disease caused directly or indirectly by a decrease in adipose tissue 'cells, for example, the ability to include malnutrition, anemia, lipodystrophy, etc. It is not restricted to these.
  • Decrease in macrophage activity refers to suppression of the action and function of macrophages, such as the production and secretion of bioactive substances such as macrophages such as MMP-9, TNF-a, and IL6, or cytodynamic force in. Or to disappear.
  • the disease caused by a decrease in macrophage activity may be a disease caused directly or indirectly by a decrease in macrophage activity, such as an immune disease or a malignant tumor.
  • “Promoting” produralurin activity specifically means that the rate of differentiation from preadipocytes to adipocytes is further increased, the induction of differentiation is further promoted, and the effect of prodarurin on adipocytes And further enhancing the effect of prodarurin on macrophages. Therefore, by promoting produral urine activity, the number of resulting adipocytes increases or the activity of adipocytes increases, or macrophages such as MMP-9, TNF-a, IL-6, etc. The production and secretion of active substances or cytosines increases.
  • Substances that promote the activity of prodara-urine of the present invention include substances that can act directly or indirectly on prodara-urine.
  • the substance that promotes produral-urine activity may be one that can promote the action of produralurin as described above, for example, by binding directly or indirectly to produralurin. .
  • prodara-yulinagost for example, prodara-yulinagost, proteolytic enzyme and the like.
  • the pharmaceutical composition of this aspect of the present invention comprises a product that promotes prodara-urine and Z or prodara-urine activity, and an excipient, additive, Z or carrier, and the like.
  • the pharmaceutical composition of the present invention may further contain one or more substances that promote produralurine activity, if desired.
  • Any dosage form of the pharmaceutical composition of the present invention can be used. It is appropriately selected depending on conditions such as a target state and a target site. For example, it may be a liquid such as an oral preparation such as a powder, a tablet, a capsule or a syrup, an injection or a drip solution.
  • the amount of the product that promotes prodara-urine and produralurin activity is determined by the age, sex, or history of the subject, and the type and severity of the disease to be treated or prevented. It is appropriately selected according to various conditions.
  • the present invention in a further aspect, comprises administering a substance that suppresses prodara-urine activity, a disease caused by an increase in adipose tissue 'cells, and an increase in Z or macrophage activity
  • the present invention provides a method for treating or preventing a disease.
  • Substances that suppress proskyulin activity, diseases caused by an increase in fat thread and tissue / cells, and diseases caused by an increase in macrophage activity are as described above.
  • the dose, administration method, administration route, number of administrations, etc. of the substance that suppresses the product activity are appropriately selected depending on various factors such as the condition of the subject and the type of disease.
  • the present invention in a still further aspect, comprises administering a product that promotes prodara-urin and Z or a product that promotes producturin activity, a disease caused by a decrease in adipose tissue 'cells, and Z
  • the present invention provides a method for treating or preventing a disease caused by a decrease in macrophage activity.
  • Substances that promote prodara-urine activity, diseases caused by a decrease in adipose tissue 'cells, and diseases caused by decreased macrophage activity are as described above.
  • the dosage, administration method, administration route, number of administrations, etc. of the substance that promotes prodara-yulin and Z or prodara-yulin activity are appropriately selected according to various factors such as the condition of the subject, the type of disease, etc. .
  • the present invention provides a disease in which an increase in adipose tissue ⁇ cells is caused.
  • the present invention relates to the use of a substance that suppresses prodanranulin activity for the manufacture of a pharmaceutical composition for treating or preventing a disease caused by increased Z or macrophage activity.
  • Substances that inhibit the activity of prodara-yulin may be added in any process for producing a pharmaceutical composition, or may be mixed with other components of the pharmaceutical composition at the time of use. Also good.
  • the amount of the substance that suppresses prodara-urine activity to be added can be appropriately selected depending on, for example, the type and severity of the disease, the condition of the subject, and the like.
  • the present invention provides a pharmaceutical thread for the treatment or prevention of a disease caused by a decrease in adipose tissue / cell and a disease caused by a decrease in Z or macrophage activity. It relates to the use of prodara-yulin and substances that promote prodara-yulin activity for the production of products.
  • Prodara-Yulin and the substance that promotes Prodara-Yulin activity may be added in any step for producing the pharmaceutical composition, or may be mixed with other components of the pharmaceutical composition at the time of use. .
  • the amount of prodara-urine and the substance that promotes prodara-urine activity to be added can be appropriately selected according to, for example, the type and severity of the disease, the condition of the subject, and the like.
  • the present invention provides a method for screening a substance that suppresses prodara-urine activity, comprising the following steps:
  • the present invention relates to a method for indicating that the candidate substance is a substance that suppresses prodara-urine activity.
  • Adipose precursor cells include, but are not limited to, those isolated from visceral adipose tissue or subcutaneous adipose tissue, mesenchymal stem cells, and those derived from stem cells such as ES cells. .
  • Methods for obtaining preadipocytes are well known to those skilled in the art. Macrophages can be obtained by appropriately selecting methods well known to those skilled in the art.
  • a method of culturing preadipocytes or macrophages in a medium containing prodara-urine The stage may be supplemented directly or indirectly with proskyulin in the adipose precursor cell or macrophage culture system.
  • the product may be dissolved in a suitable solvent such as PBS and added to the medium, or the culture of host cells transduced with an expression vector containing the cDNA encoding product product-urine may be used. Kiyo may be added to the medium or supplied by macrophages.
  • the addition of programming to the culture system of preadipocytes may be performed by co-culturing preadipocytes with macrophages or by adding a culture supernatant of macrophages.
  • Macrophages infiltrated with adipose precursor cells and adipocytes are observed in adipose tissue in vivo. Therefore, in order to perform screening under conditions close to the environment in vivo, Prodara-Yulin was co-cultured with macrophages. The power of adding is more preferable.
  • the addition of Prodara-Yulin to the macrophage culture system may be carried out by being produced by itself, or by adding a culture supernatant of macrophages cultivated separately.
  • As the medium RPMI 1640 medium, DMEMZF-12 medium and the like are known, and can be appropriately selected and used.
  • the number of fat cells is calculated by microscopic observation, and the size, number, fat content, etc. of fat droplets are observed by oil red O staining.
  • Markers that are known to decrease or increase in expression from preadipocytes to adipocytes such as aP2, CD36, adiponectin, resistin, GLUT4, TNF-a, PAI- Measurement of 1 etc. by quantitative PCR or immunoblot.
  • adipocytes As a means of examining the activity of adipocytes, for example, immunization with substances known to be produced and secreted by adipocytes such as aP2, CD36, adiponectin, resistin, GLUT4, TNF-a, PAI-1 Examples include measuring by plotting, measuring the expression of genes encoding powerful substances by quantitative PCR, and quantifying the amount of fatty acid secreted by catecholamine supplements.
  • a means for examining the macrophage activity for example, it is performed by examining the production amount of a marker substance that changes the production amount of macrophage power when activated. Specifically, it is a powerful marker that production increases with macrophage activity. Investigate the amount of production of car substances such as MMP-9, TNF-a, IL-6, etc., or marker substances such as adiponectin, whose production is likely to decrease with macrophage activation. Is done. Examples of the means for examining the production amount of the marker substance include, but are not limited to, quantitative PCR, immunoblot, ELISA, bioassay and the like.
  • Substances obtainable by a powerful screening method are suitable, for example, for the treatment or prevention of diseases caused by increased adipose tissue 'cells and diseases caused by increased Z or macrophage activity. it is conceivable that.
  • Yet another embodiment of the present invention is a method for screening a substance that promotes prodara-urine activity.
  • a candidate substance in the presence of a candidate substance, if preadipocyte force promotes differentiation into adipocytes or increases adipocyte activity, or increases macrophage activity,
  • the substance is shown to be a substance that promotes Prodara-Yulin activity.
  • candidate substances include, but are not limited to, proteolytic enzyme analogs, derivatives or mutants.
  • Substances that can be obtained by powerful screening methods are considered to be suitable for the treatment or prevention of diseases that are caused by, for example, a decrease in fat tissue 'cells, and diseases that are caused by a decrease in Z or macrophage activity. .
  • the present invention relates to a substance that suppresses or promotes prodara-urine activity, which can be obtained by the above screening method.
  • the present invention provides, in a still further aspect, a disease whose pathogenesis is caused by an increase or decrease in adipose tissue 'cells, which comprises a substance that suppresses or promotes prodara-urine activity, which can be obtained by the screening method described above.
  • the present invention relates to a pharmaceutical composition for treating or preventing a disease caused by an increase or decrease in Z or macrophage activity.
  • the pharmaceutical composition comprises a substance that suppresses or promotes the produra-urine activity that can be obtained by the screening method, and an excipient, an additive, and Z or a carrier.
  • the pharmaceutical composition contains, in addition to the substance that suppresses or promotes the producturin activity obtainable by the above screening method, further one or more substances that inhibit or promote the producta-urine activity. .
  • Agent of the pharmaceutical composition The shape has already been explained.
  • the present invention relates to a kit for screening for a substance that suppresses or promotes produralulin activity, which is used in the screening method.
  • the kit of the present invention may include a medium, a culture vessel, a means for examining differentiation of preadipocytes into adipocytes, activity of fat cells, or macrophage activity, and the like.
  • the instruction manual is attached to the kit. The above screening can be performed quickly and easily using a powerful kit.
  • the present invention in another aspect, relates to a disease or predisposition to which an increase or decrease in adipose tissue cells of a subject is pathogenic and a disease or predisposition to which an increase or decrease in Z or macrophage activity is pathogenic
  • the present invention relates to a test method comprising obtaining a sample from a subject and assessing the amount of produra-urine and Z or activity in the sample.
  • the disease may be caused directly or indirectly by an increase or decrease in the amount of prodara-urine and Z or activity.
  • obesity diabetes, hypertension, hyperlipidemia
  • examples include metabolic syndrome, arteriosclerotic disease, ischemic heart disease, inflammatory disease, arteriosclerosis, cirrhosis, malnutrition, ulcer, lipodystrophy, immune disease, and malignant tumor.
  • Preferred are obesity, metabolic syndrome, and arteriosclerotic disease.
  • the sample may be any sample as long as the target force is obtained.
  • serum for example, serum, a puncture specimen of preadipose tissue, and the like.
  • the means for assessing the amount and Z or activity of prodara-urine may be directly assessing or indirectly assessing the amount and product or Z or activity of prodara-urine. Also good.
  • the expression of proskyulin may be measured by ELISA, immunoplot, or quantitative PCR, or the preadipocytes are cultured in a medium supplemented with the sample, and differentiation from the preadipocytes into adipocytes is performed. It may be examined, or a substance in which the macrophage is cultured in a medium supplemented with the sample and production from macrophages is promoted or suppressed by prodara-ulin, such as MMP-9, TNF-a, IL The expression level or production / secretion level of 6 etc. may be measured.
  • Human monocyte-derived macrophages were cultured in RPMI 1640 (Gibco) containing 10% human serum for 7 days at 37 ° C, and then cultured in serum-free RPMI 1640 for 24 hours. Next, the culture supernatant was concentrated by 80% ammonium sulfate precipitation, and desalted using a PD-10 column (Amersham Pharmacia). The eluate was purified through an apolipoprotein A—I affinity column (Pierce). The purified protein was identified as a single protein of about 80 kDa by SDS-PAGE (see Figure 1). The internal amino acid sequence of this protein was determined by in-gel digestion with V8 peptidase and found to be prodara-urine (hereinafter also referred to as PEPI), a kind of pro-inflammatory site force in. I was strong.
  • PEPI prodara-urine
  • RNA was extracted at 0, 1, 3, 5, 7, and 10 days. Quantitative PCR (internal standard: GAP DH) was performed using TaqMan [registered trademark] probe (Applied Bio Systems) using powerful RNA as a recording model. The results are shown as relative values when the expression level on day 0 is taken as 1 (see FIG. 2). It was found that the expression of prodarulin increases with the macrophage distribution. As controls, CD14, whose expression decreases with macrophage differentiation, and SR-A and CD36, whose expression increases, were measured.
  • Human adipose precursor cells were co-cultured with macrophages for 7 days in DMEM / F-12 medium containing 66nM insulin, 0.033mM piotin, 0.017mM nontenthenic acid, 10% human serum, and then stained with oil red O. .
  • preadipocytes cultured in the absence of macrophages were used.
  • a medium containing 20 gZm 1 HDL or 10 / zg / ml apolipoprotein A—I in the above-mentioned adipose precursor cells was used. And cultured.
  • Human adipose precursor cells were co-cultured with macrophages in 10% human serum-containing DMEM / F-12 medium supplemented with 50 ⁇ g / ml anti-prodara-urine antibody (anti-PEPI antibody) for 7 days, followed by oil red O Staining was performed.
  • Anti-Prodara-Yulin antibody suppresses the differentiation of adipocytes (see Fig. 5), so that Prodara-Yulin secreted by macrophages also promotes the differentiation of preadipocytes into adipocytes. I understood.
  • C. proongulin promotes differentiation of preadipocytes into adipocytes, and its suppression by HDL and apolipoprotein AI
  • Prodara-Yulin cDNA was ligated into the expression vector pcDNA3.1 (Invitorogen) and transfected into 293 cells.
  • the preadipocytes were cultured for 7 days in DMEMZF-12 medium containing 10% ushi fetal serum supplemented with the obtained culture supernatant, and then oil red O staining was performed.
  • cultured preadipocytes in the absence of prodara-yulin were used. It was further confirmed that prodanranulin promotes the differentiation of preadipocytes into adipocytes (see Fig. 6).
  • adipose precursor cells are cultured in a medium supplemented with HDL and apolipoprotein AI, and It was confirmed that the promotion of differentiation into adipocytes was suppressed by HDL and apolipoprotein AI (see Fig. 6).
  • Human monocyte-derived macrophages were cultured in DMEMZF-12 medium containing 10% human serum for 7 days. Next, after culturing in RPMI 1640 medium containing the culture supernatant of 293 cells transfected with an expression vector containing prodara-urine cDNA, macrophages were recovered and RNA was extracted. Quantitative PCR (internal standard: GAPDH) was performed using TaqMan (registered trademark) probe, and the expression of TNF- ⁇ and MMP-9 was measured.
  • GAPDH quantitative PCR
  • TNF- ⁇ and ⁇ -9 which is expressed in activated macrophages and is known to induce differentiation of preadipocytes, is increased by prodara-yulin, and this increase is due to HDL, apolipoprotein It was found that it was suppressed by A—I (see Figures 7 and 8).
  • Human monocyte-derived macrophages are cultured in DMEMZF-12 medium containing 10% human serum containing anti-prodara-urine antibodies (M12, N19, and S15) for 1 day, RNA is extracted, and TaqMan (registered trademark) probe is used V and quantitative PCR (internal standard: GAPDH) were performed to measure the expression of MMP-9. It was found that anti-Prodara-Yulin antibody suppressed MMP-9 expression (see Fig. 9).
  • prodara-urine activity for treating or preventing a disease caused by an increase or decrease in adipose tissue / cells and a disease caused by an increase or decrease in Z or macrophage activity is improved.
  • a pharmaceutical composition comprising a substance that suppresses or promotes, and a disease caused by an increase or decrease in fat thread and tissue cells and a disease caused by an increase or decrease in Z or macrophage activity
  • a disease or predisposition to the pathogenesis of an increase or decrease in adipose tissue cells characterized by the method of screening the substance and the substance obtainable thereby, and prodara-urine amount and Z or activity , And increased Z or macrophage activity
  • a method for testing a disease whose cause is a decrease or a predisposition thereof, etc. such as development of preventive, therapeutic or diagnostic agents for diseases such as obesity and metabolic syndrome It can be used in the field of manufacturing, the field of health foods, the research field of fat precursor cells or macrophage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention a pour objet une préparation pharmaceutique pour le traitement prophylactique ou thérapeutique d'une maladie induite par la croissance de cellules ou de tissus adipeux, et/ou d'une maladie induite par la croissance de l'activité des macrophages, ladite préparation pharmaceutique comprenant une substance susceptible d'inhiber l'activité de la progranuline. La présente invention a également pour objet une préparation pharmaceutique pour le traitement prophylactique ou thérapeutique d'une maladie induite par la réduction des cellules ou des tissus adipeux, et/ou d'une maladie induite par la réduction de l'activité des macrophages, ladite préparation pharmaceutique comprenant de la progranuline et/ou une substance susceptible de promouvoir l'activité de la progranuline. La présente invention a en outre pour objet une méthode de recherche par criblage d'une substance susceptible d'inhiber ou de promouvoir l'activité de la progranuline, ainsi qu'une substance obtenue à l'aide de la méthode, etc.
PCT/JP2006/312428 2005-06-28 2006-06-21 Préparation pharmaceutique comprenant une substance susceptible d'inhiber ou de promouvoir l'activité de la progranuline et méthode de criblage pour la recherche d'une substance susceptible d'inhiber ou de promouvoir l'activité de la progranuline WO2007000924A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005-188507 2005-06-28
JP2005188507 2005-06-28

Publications (1)

Publication Number Publication Date
WO2007000924A1 true WO2007000924A1 (fr) 2007-01-04

Family

ID=37595178

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/312428 WO2007000924A1 (fr) 2005-06-28 2006-06-21 Préparation pharmaceutique comprenant une substance susceptible d'inhiber ou de promouvoir l'activité de la progranuline et méthode de criblage pour la recherche d'une substance susceptible d'inhiber ou de promouvoir l'activité de la progranuline

Country Status (1)

Country Link
WO (1) WO2007000924A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009010045A1 (fr) * 2007-07-16 2009-01-22 Johann Wolfgang Goethe-Universität Frankfurt am Main Utilisation d'une granuline ou d'un composé analogue à la granuline pour la thérapie ou la prophylaxie des douleurs chroniques
KR100896328B1 (ko) 2008-12-03 2009-05-07 주식회사 에디포젠 대사성 질환의 진단 마커로 유용한 프로그레뉼린
US8999365B2 (en) 2005-02-01 2015-04-07 Sinclair Pharmaceuticals Limited Prevention of bacterial contamination

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07502892A (ja) * 1991-12-13 1995-03-30 エスペリオン　セラピューティクス　インコーポレーテッド アポリポ蛋白質の分子変異体の２量体およびその製造方法
JP2000509020A (ja) * 1996-03-29 2000-07-18 ダリオ・ボッフェリ コレステロールおよび他の脂質の取り込みを阻害する両親媒性分子
WO2002022886A2 (fr) * 2000-09-18 2002-03-21 Wisconsin Alumni Research Foundation Expression de genes dans le diabete sucre et la resistance a l'insuline
WO2003018047A2 (fr) * 2001-08-20 2003-03-06 Zlb Bioplasma Ag Lipoproteines de haute densite (hdl) pour le traitement des accidents vasculaires cerebraux (avc) et autres evenements ischemiques
JP2004504355A (ja) * 2000-07-20 2004-02-12 ツェットエルベー　ビオプラスマ　アクチエンゲゼルシャフト 不安定狭心症の治療方法
WO2004045544A2 (fr) * 2002-11-19 2004-06-03 A & G Pharmaceuticals, Inc. Anticorps du recepteur du facteur de croissance autocrine et methodes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07502892A (ja) * 1991-12-13 1995-03-30 エスペリオン　セラピューティクス　インコーポレーテッド アポリポ蛋白質の分子変異体の２量体およびその製造方法
JP2000509020A (ja) * 1996-03-29 2000-07-18 ダリオ・ボッフェリ コレステロールおよび他の脂質の取り込みを阻害する両親媒性分子
JP2004504355A (ja) * 2000-07-20 2004-02-12 ツェットエルベー　ビオプラスマ　アクチエンゲゼルシャフト 不安定狭心症の治療方法
WO2002022886A2 (fr) * 2000-09-18 2002-03-21 Wisconsin Alumni Research Foundation Expression de genes dans le diabete sucre et la resistance a l'insuline
WO2003018047A2 (fr) * 2001-08-20 2003-03-06 Zlb Bioplasma Ag Lipoproteines de haute densite (hdl) pour le traitement des accidents vasculaires cerebraux (avc) et autres evenements ischemiques
WO2004045544A2 (fr) * 2002-11-19 2004-06-03 A & G Pharmaceuticals, Inc. Anticorps du recepteur du facteur de croissance autocrine et methodes

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CIRCULATION, vol. 112, no. 17, SUPPL. S, 25 October 2005 (2005-10-25), pages PU371 *
DATABASE BIOSIS [online] MATSUYAMA A. ET AL.: "Potent proinflammatory functions of macrophage-derived proepitherin/progranulin are suppressed through its binding to HDL and apolipoprotein A-1", accession no. STN Database accession no. (PREV20060047508) *
HAN J. ET AL.: "Regulation of peroxisome proliferator-activated receptor-gamma-mediated gene expression. A new mechanism of action for high density lipoprotein", J. BIOL. CHEM., vol. 277, no. 26, 2002, pages 23582 - 23586, XP003007191 *
LU R. ET AL.: "Inhibition of PC cell-derived growth factor (PCDGF, epithelin/granulin precursor) expression by antisense PCDGF cDNA transfection inhibits tumorigenicity of the human breast carcinoma cell line MDA-MB-468", PROC. NATL. ACAD. SCI. USA, vol. 97, no. 8, 2000, pages 3993 - 3998, XP002963204 *
MATSUYAMA A. ET AL.: "Ko Seikatsu Shukanbyo Yaku Screening-kei no Kakuritsu-Macrophage tono Kyobaiyo ni yoru Naizo Shibo Bunka Baiyokei no Kakuritsu", THE JOURNAL OF THE JAPANESE SOCIETY OF INTERNAL MEDICINE, vol. 95, no. SPECIAL EXTRA ISSUE, 20 February 2006 (2006-02-20), pages 149, XP003008993 *
SERRERO G.: "Autocrine growth factor revisited: PC-cell-derived growth factor (progranulin), a critical player in breast cancer tumorigenesis", BIOCHEM BIOPHYS RES COMMUN, vol. 308, no. 3, 2003, pages 409 - 413, XP004444552 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8999365B2 (en) 2005-02-01 2015-04-07 Sinclair Pharmaceuticals Limited Prevention of bacterial contamination
WO2009010045A1 (fr) * 2007-07-16 2009-01-22 Johann Wolfgang Goethe-Universität Frankfurt am Main Utilisation d'une granuline ou d'un composé analogue à la granuline pour la thérapie ou la prophylaxie des douleurs chroniques
JP2010533660A (ja) * 2007-07-16 2010-10-28 ヨハン ウォルフガング ゲーテ−ウニベルジテート フランクフルト アム マイン 慢性疼痛の治療又は予防のためのグラニュリン又はグラニュリン様化合物の使用
US8367616B2 (en) 2007-07-16 2013-02-05 Johann Wolfgang Goethe-Universitat Frankfurt Am Main Use of a granulin or a granulin-like compound in the therapy or prophylaxis of chronic pains
US9655947B2 (en) 2007-07-16 2017-05-23 Johann Wolfgang Goethe-Universitat Frankfurt Am Main Use of a granulin or a granulin-like compound for the therapy or prophylaxis of chronic pain
KR100896328B1 (ko) 2008-12-03 2009-05-07 주식회사 에디포젠 대사성 질환의 진단 마커로 유용한 프로그레뉼린

Similar Documents

Publication Publication Date Title
Dehkhoda et al. The growth hormone receptor: mechanism of receptor activation, cell signaling, and physiological aspects
Kahles et al. Osteopontin: A novel regulator at the cross roads of inflammation, obesity and diabetes
Chen et al. GLP-1/GLP-1R signaling in regulation of adipocyte differentiation and lipogenesis
Elinav et al. Competitive inhibition of leptin signaling results in amelioration of liver fibrosis through modulation of stellate cell function
Hu et al. MicroRNA-155 inhibition attenuates endoplasmic reticulum stress-induced cardiomyocyte apoptosis following myocardial infarction via reducing macrophage inflammation
EP2572730A1 (fr) Procédé pour la prévention ou le traitement du syndrome métabolique
Du et al. A novel role of kallikrein-related peptidase 8 in the pathogenesis of diabetic cardiac fibrosis
EP2565275B1 (fr) Procédé de traitement de complications vasculaires en utilisant des modulateurs de TRX et TRXNIP
EP2413968B1 (fr) Produits thérapeutiques inhibiteurs de la sémaphorine 3c (sema3c), procédés et utilisations
Sekar et al. Saturated fatty acids promote chondrocyte matrix remodeling through reprogramming of autophagy pathways
Kim et al. Hinokitiol increases the angiogenic potential of dental pulp cells through ERK and p38MAPK activation and hypoxia-inducible factor-1α (HIF-1α) upregulation
Wu et al. Palmitic acid aggravates inflammation of pancreatic acinar cells by enhancing unfolded protein response induced CCAAT-enhancer-binding protein β–CCAAT-enhancer-binding protein α activation
Wang et al. [Retracted] Amidation‐Modified Apelin‐13 Regulates PPARγ and Perilipin to Inhibit Adipogenic Differentiation and Promote Lipolysis
Shiraki et al. Deficiency of stress‐associated gene Nupr1 increases bone volume by attenuating differentiation of osteoclasts and enhancing differentiation of osteoblasts
Zhang et al. SENP3-mediated PPARγ2 DeSUMOylation in BM-MSCs potentiates glucocorticoid-induced osteoporosis by promoting adipogenesis and weakening osteogenesis
Niwa et al. IRAP deficiency attenuates diet-induced obesity in mice through increased energy expenditure
Diao et al. Potential therapeutic activity of berberine in thyroid-associated ophthalmopathy: inhibitory effects on tissue remodeling in orbital fibroblasts
WO2007000924A1 (fr) Préparation pharmaceutique comprenant une substance susceptible d'inhiber ou de promouvoir l'activité de la progranuline et méthode de criblage pour la recherche d'une substance susceptible d'inhiber ou de promouvoir l'activité de la progranuline
Bonner et al. Expression of functional receptor activity modifying protein 1 by airway epithelial cells with dysregulation in asthma
Sherriff-Tadano et al. Antifibrotic effects of hepatocyte growth factor on scleroderma fibroblasts and analysis of its mechanism
Crozier et al. CCK-induced pancreatic growth is not limited by mitogenic capacity in mice
WO2013040391A2 (fr) Nouveaux marqueurs de surface pour tissus adipeux
WO2012097126A2 (fr) Traitement par l'il-25 de l'obésité et des troubles métaboliques
Kim et al. xCT-mediated glutamate excretion in white adipocytes stimulates interferon-γ production by natural killer cells in obesity
Rankouhi et al. Oncostatin M: risks and benefits of a novel therapeutic target for atherosclerosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: JP

122 Ep: pct application non-entry in european phase

Ref document number: 06767087

Country of ref document: EP

Kind code of ref document: A1